Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider directly owned 130,142 shares in the company, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Sensei Biotherapeutics Trading Down 6.4%
NASDAQ SNSE traded down $1.35 during trading hours on Monday, hitting $19.79. The company’s stock had a trading volume of 65,516 shares, compared to its average volume of 205,528. Sensei Biotherapeutics, Inc. has a 52 week low of $5.60 and a 52 week high of $36.76. The company has a market capitalization of $26.52 million, a PE ratio of -0.14 and a beta of -0.25. The company’s 50-day simple moving average is $26.41 and its two-hundred day simple moving average is $18.54.
Sensei Biotherapeutics (NASDAQ:SNSE – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83). Research analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current fiscal year.
Institutional Investors Weigh In On Sensei Biotherapeutics
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on SNSE shares. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Cantor Fitzgerald started coverage on shares of Sensei Biotherapeutics in a research report on Friday. They set an “overweight” rating on the stock. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price on the stock. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $46.25.
View Our Latest Analysis on SNSE
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Read More
- Five stocks we like better than Sensei Biotherapeutics
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
